Below is a list of Horizon Pharma PLC (NASDAQ:HZNP) latest ratings and price target changes. The stock rose 2.02% or $0.28 reaching $14.11. About 1.33M shares traded. BidaskClub raised shares of Horizon Pharma PLC from a "hold" rating to a "buy" rating in a research report on Saturday, June 24th. It has underperformed by 44.83% the S&P500. It is down 1.69% since September 11, 2016 and is uptrending. It has underperformed by 40.21% the S&P500. It was reported on Sep, 12 by Barchart.com. The analyst recommendations from a month ago are 9 Buy, 0 Overweight, 0 Sell, 2 Hold and 0 Underweight. Therefore 77% are positive. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $21.98. The stock has "Buy" rating by Goldman Sachs on Monday, June 6. As per Monday, November 28, the company rating was upgraded by Evercore. Horizon Pharma PLC (NASDAQ:HZNP) has declined 28.13% since September 12, 2016 and is downtrending. Mizuho downgraded Horizon Pharma PLC (NASDAQ:HZNP) on Friday, December 9 to "Neutral" rating. Iguana Health Limited Liability reported 50,000 shares or 0.48% of all its holdings. Oxford Asset stated it has 0.05% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP). Piper Jaffray maintained it with "Buy" rating and $18.0 target in Friday, September 8 report. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Suntrust Robinson maintained it with "Buy" rating and $63 target in Monday, October 19 report. The stock of Essex Property Trust Inc (NYSE:ESS) earned "Overweight" rating by KeyBanc Capital Markets on Friday, December 16.
Investors sentiment decreased to 1.02 in Q4 2016. Analysts expect next quarter's EPS to be $0.23 and the next full year EPS is projected to be $1.25.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.29. 700 are owned by Carroll Fincl Associates.
As of the end of the quarter Rhenman & Partners Asset Management Ab had acquired a total of 670,768 shares growing its position 38.3%. Proshare Ltd reported 134,759 shares. Jpmorgan Chase And holds 494,506 shares. 244,533 were reported by Ubs Asset Mngmt Americas.
BNP Paribas Arbitrage SA boosted its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 432.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). Moreover, Raymond James Assoc has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP). 3,150 were reported by Da Davidson And Com. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company's stock valued at $473,000 after buying an additional 368 shares in the last quarter. Hong Kong-based Point72 Asia (Hong Kong) has invested 0.04% in XPO Logistics Inc (NYSE:XPO). State Street owns 4.34M shares for 0.01% of their portfolio. Hudock Capital Grp Lc, a Pennsylvania-based fund reported 1,821 shares. Savings Bank Of Montreal Can holds 131,513 shares or 0% of its portfolio.
Since May 10, 2017, it had 1 insider purchase, and 0 selling transactions for $94,800 activity. The insider GREY MICHAEL G bought 10,000 shares worth $94,800. It also upped Sysco Corp (NYSE:SYY) stake by 8,000 shares and now owns 56,000 shares. Twenty First Centy Fox Inc (NASDAQ:FOXA) was raised too.
Investors sentiment increased to 1.58 in 2016 Q4. Its up 0.31, from 1.51 in 2016Q3. 67 funds opened positions while 253 raised stakes. Cls Invs Llc reported 0% stake. Stifel invested in 57,180 shares. Citadel Advsr Limited Liability Company has 394,909 shares. United Capital Advisers Ltd Company invested in 114,763 shares or 0.02% of the stock. Wells Fargo & Communications Mn invested in 0% or 443,109 shares. The Ontario - Canada-based Manufacturers Life Insurance The has invested 0% in Atlantic Power Corp (NYSE:AT). 31,147 are held by Blackrock Inc. Rhumbline Advisers holds 0.01% or 120,153 shares. (NASDAQ:CEMP), its shares were trading at $3.15 a retreat of $0, on the trading floor. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It now has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.